These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11642523)

  • 1. Cocaine-Induced raynaud's phenomenon and ischaemic finger necrosis.
    Balbir-Gurman A; Braun-Moscovici Y; Nahir AM
    Clin Rheumatol; 2001; 20(5):376-8. PubMed ID: 11642523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
    McGrath SE; Webb A; Walker-Bone K
    J Clin Oncol; 2013 Feb; 31(4):e51-2. PubMed ID: 23270004
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloprost treatment for refractory Raynaud's phenomenon in two infants.
    Shouval DS; Mukamel M; Zulian F; Amir J; Harel L
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.
    Watson HR; Belcher G
    Ann Rheum Dis; 1991 Jun; 50(6):359-61. PubMed ID: 1711834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis.
    Warkentin TE; Whitlock RP; Teoh KH
    Am J Hematol; 2004 Jan; 75(1):56-62. PubMed ID: 14695634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon.
    Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG
    Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine and arsenic-induced Raynaud's phenomenon.
    Noël B
    Clin Rheumatol; 2002 Aug; 21(4):343-4. PubMed ID: 12296288
    [No Abstract]   [Full Text] [Related]  

  • 19. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
    Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER
    Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.